Sandra Horning

Roche’s phase III CAPSTONE-2 study showed superior efficacy of baloxavir marboxil in reducing influenza symptoms in people at high risk of complications from the flu

Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of…

6 years ago

Roche’s Tecentriq in combination with Avastin receives FDA Breakthrough Therapy Designation as initial treatment for advanced or metastatic hepatocellular carcinoma

BASEL, 18-Jul-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA)…

6 years ago

Roche: Phase III IMpower131 study met its co-primary endpoint of progression-free survival of people with a type of advanced squamous lung cancer

BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its…

6 years ago

Roche’s Lucentis is the first and only FDA-approved medicine to treat diabetic retinopathy

First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based…

7 years ago

New Data on Roche’s OCREVUS To be Presented at AAN

Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis BASEL, 24-Apr-2017 —…

7 years ago

Roche’s Perjeta recommended for approval in EU as pre-surgery breast cancer treatment

The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the…

9 years ago

Roche: New data in rheumatoid arthritis and other severe autoimmune conditions will be presented at European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, 10-13 June 2015

40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) –…

9 years ago

Roche subcutaneous formulation of RoACTEMRA received European Commission approval for moderate to severe rheumatoid arthritis treatment

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 —…

10 years ago